Abstract 3547
Background
With the increased use of ICIs among cancer patients, there is growing interest in understanding the outcome and management of irAEs. This study addressed this knowledge gap by examining the real-world outcomes in patients experiencing irAEs.
Methods
An observational study was conducted using the Premier Healthcare Database, a US national hospital discharge database (Mar 2015-Dec 2017). Twenty-eight distinct types of irAEs per the ASCO practice guidelines were identified. Patients with ICD-9/10 codes for NSCLC, RCC, UC, or MCC and one of 28 irAEs during the study period were included. Index irAE visits were defined as the first visit with a confirmed ICI usage during a 90-day look-back period from the first irAE. Patients were then followed for 90 days post-irAE to determine irAE-related inpatient admissions, all-cause in-hospital mortality, and ICI re-initiation.
Results
15,277 distinct irAEs occurred across 13,030 patients, with 5,732 (38%) of irAE events with an inpatient index visit. Among the 6590 patients having ≥1 irAEs, 44% had 1 irAE of any type, 25% had 2, 14% had 3, and 17% had ≥4 irAEs. Among the 28 types of irAEs, inpatient index visits were most common for myocarditis, transverse myelitis, and toxic epidermal necrolysis (all 100%), and least common for acquired hemophilia (0%), polymyalgia-like syndrome (10%), and adrenal insufficiency (10%). During the follow-up period, patients with inpatient index admissions had higher (p < 0.001) subsequent inpatient admissions and higher mortality, and lower (p < 0.001) ICI re-initiation (Table).Table:
1284P
Index Visit Type | |||
---|---|---|---|
Clinical outcome: 90 days following index irAE | All | Inpatient | Outpatient |
irAE-related inpatient admission | 23% | 26%* | 19%* |
No ICI re-initiation | 47% | 70%** | 28%** |
All-cause inpatient mortality | 12% | 23%*** | 6%*** |
p < 0.001,
**p < 0.001,
***p < 0.001
Conclusions
Approximately half of patients receiving an ICI experienced an irAE that required clinical management in inpatient or outpatient setting. Occurrence of irAEs was associated with treatment discontinuation. Overall, irAE cases with inpatient index visits tended to have poor outcomes and required more follow-up management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
EMD Serono, Inc.
Funding
This study was sponsored by EMD Serono, Inc, a business of Merck Healthcare KGaA, Darmstadt, Germany, and is part of an alliance between EMD Serono/Merck Healthcare KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY, USA.
Disclosure
S. George: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Research grant / Funding (institution): Novartis; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Corvus; Advisory / Consultancy: Genentech; Advisory / Consultancy: Sanofi/Genzyme; Advisory / Consultancy, Research grant / Funding (institution): Pfizer, Inc; Research grant / Funding (institution): Acceleron; Research grant / Funding (institution): Merck ; Research grant / Funding (institution): Agensys; Research grant / Funding (institution): Eisai; Advisory / Consultancy: EMD Serono, Inc. Y. Zheng: Full / Part-time employment, current employment (self): EMD Serono, Inc; Full / Part-time employment, previous employment (self) : Janssen; Licensing / Royalties, Full / Part-time employment, spouse and immediate family: Shire (now Takeda); Full / Part-time employment, spouse: Eli Lilly. R. Kim: Full / Part-time employment: Pfizer, Inc.; Shareholder / Stockholder / Stock options: Exelixis. T. Yu: Full / Part-time employment: EMD Serono, Inc. J. Dreyfus: Shareholder / Stockholder / Stock options, Full / Part-time employment: Premier, Inc. J.A. Gayle: Full / Part-time employment: Premier, Inc. C. Wassel: Full / Part-time employment: Premier, Inc. H. Phatak: Full / Part-time employment: EMD Serono, Inc.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
1595 - Serum Netrin-1 as a Biomarker for Colorectal Cancer Detection
Presenter: Jinzhou Zhu
Session: Poster Display session 3
Resources:
Abstract